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ABSTRACT
Background. Tremor is one of the most common movement disorders. It does not usually respond to first-line drug treatments 
(e.g. propranolol, primidone, anticholinergics, gabapentin and clonazepam) due to side effects and frequent dose limitations. 
Botulinum toxin type A (BoNT-A) has been widely used to treat tremor, but its efficacy and safety are uncertain.
Aims. To evaluate the efficacy and safety of BoNT-A in the treatment of hand tremor.
Methods. We searched the MEDLINE, EMBASE, PsycINFO and Cochrane Library databases for relevant randomised controlled 
trials of the effects of BoNT-A injections on tremors, up to 20 February 2020. A meta-analysis of comparative effects was per-
formed using R studio software, and publication bias was examined using Egger’s test.
Results. Six studies examining a total of 245 participants with tremor were included in the meta-analysis. The primary outcome 
of meta-analysis showed no difference in clinical tremor scale scores between the BoNT-A group versus the placebo group 
(standardised mean difference (SMD): -0.42, 95% confidence interval (CI): -1.94 to 1.10; I2 = 96%). For clinical tremor scale scores, 
subgroup analyses suggested that the BoNT-A group may differ in terms of multiple sclerosis (MS) related tremor (SMD: -1.10; 
95% CI: -2.17 to -0.04; I2 = 79%) compared to a placebo, but the difference did not exist in the outcome of essential tremor (ET) or 
hand tremor (MD: -1.31; 95% CI: -3.39; 1.31; I2 = 97%). Grip strength (MD: -1.25, 95% CI: -5.99 to 3.50, I2 = 97%) was slightly lower 
in the BoNT-A group, but the difference was not significant. The incidence of adverse events (AEs), including hand weakness 
(RR: 2.96, 95% CI: 1.40 to 6.24, I2 = 37%), was significantly greater in the BoNT-A group than in the placebo group. Two studies 
were assessed as having an overall low risk of bias.
Conclusions. Our study confirms that BoNT-A injections are unlikely to have an impact on patients with hand tremors. Howe-
ver, subgroup analysis suggested that BoNT-A injections could have possible benefits in MS-related tremor. While moderate to 
severe hand weakness AEs often limits their use in clinical practice, additional well-designed double-blind, placebo-controlled 
trials are needed to provide more robust conclusions. 
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Introduction
Tremor is defined as a rhythmic and involuntary move-
ment of any body part [1]. The prevalence of essential tremor 
(ET) is markedly greater than that of Parkinson’s Disease (PD) 
[2, 3], with an overall estimated prevalence of 0.9% to 2.2%, 
and 4.6% of the population aged ≥ 65 years [4]. PD affects 
approximately 1% of the population over the age of 60, with 
an incidence of resting or postural tremor [5]. The prevalence 
of tremor in the multiple sclerosis (MS) population ranges 
from 25% to 58% [6]. Tremor is a symptom of many disorders. 
In addition to ET [2], PD [5], and MS [6], other conditions 
also cause tremor, such as dystonic tremor and lesions to the 
midbrain or cerebellar structures (rubral tremor). Tremor 
shows a limited response to the pharmacological treatments 
currently available [7]. 
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Tremors can be classified as being postural, rest or action 
tremors. Surgical treatments such as deep brain stimulation 
(DBS) are effective for a number of movement disorders, in-
cluding ET, PD tremor and tremor due to MS [8]. For tremor 
drug options [9], propranolol and primidone are considered 
the drugs of first choice in ET tremor reduction. Dystonic 
limb tremor may respond to anticholinergics. Gabapentin and 
clonazepam are often recommended for orthostatic tremor. MS 
tremor responds only poorly to drug treatment. For patients with 
severe MS tremor, thalamic deep brain stimulation has been 
recommended. Although drug options (e.g. propranolol and 
primidone) are considered first-line treatments and are effective 
in the management of ET tremor [10, 11], more than 30% of pa-
tients with ET do not respond to these agents. In addition, their 
use is limited, particularly among people over 70 years old [12]. 
With pharmacological or surgical management limited 
due to adverse events and long-term efficacy, an investigation 
into the effects of alternative treatments for tremor seemed to 
be worthwhile.
Botulinum toxin type A (BoNT-A) is increasingly often 
used as a treatment for focal tremors [13], but no meta-anal-
yses of the effects of BONT-A on tremor in patients have 
been performed. As related clinical research is accumulating, 
a meta-analysis designed to identify the efficacy and safety of 
BoNT-A for tremors is timely. This present study aimed to as-
sess the effectiveness and safety of BoNT-A for hand tremors in 
adults, including patients with ET, PD tremor and MS tremor.
Methods
Eligibility
Types of study 
Randomised controlled trials (RCTs) comparing the ef-
fects of BoNT-A and control therapy on patients with tremor 
were evaluated for inclusion, regardless of blinding, language, 
publication status, and length of trial.
Types of participants
Study participants were adults (aged 18 or older) with con-
firmed clinical diagnoses of any type of tremor according to the 
criteria proposed by the Tremor Investigation Group. Gender 
or ethnicity restrictions were not applied. According to the 
principle of PICOS in evidence-based medicine, studies were 
included if they met the following criteria for participants: all 
subjects aged ≥ 18 years with a diagnosis of PD, ET, MS or other 
tremor disorder. The following were excluded: observational 
studies, retrospective studies, conference summaries, animal 
studies, reviews, and duplicate articles.
Types of intervention
Botulinum toxin injections for tremor were compared to 
control injections. We did not exclude trials based on the dose 
or route of administration.
Types of outcome measure
The primary outcome measures for evaluating the sever-
ity of tremors of the limb in patients with ET, PD and MS 
included the following clinical assessment comparisons: the 
Fahn-Tolosa-Marin Tremor Rating Scale (FTM-TRS) (range 
0–4 points) rates tremor severity based on tremor amplitude 
from 0 (no tremor) to 4 (severe tremor) in each part of the 
body; the Essential Tremor Rating Assessment Scale (TET-
RAS) consists of ten items scoring from 0–4 points (0 = no 
visible tremor); and the Tremor Clinical Rating Scale (TCRS) 
has a range of scores from 0 (no tremor) to 4 (severe tremor) 
points. Secondary outcomes included grip strength (measured 
by a dynamometer or by a clinical rating of the strength of 
the wrist flexors and extensors), hand weakness (defined as 
a percentage decrease in force of the whole hand) as adverse 
events, kinetic tremor severity (0–4), and postural tremor 
severity (0–4).
Data source and search strategy
A search of Medline, CENTRAL (Cochrane Library), 
PsycINFO and EMBASE databases from their inception until 
February 2020 was performed to identify potentially qualified 
studies. Medical Subject Heading (MeSH) terms, key words 
and text words were used as the search strategy (details are 
presented in Table S1). This strategy was then adapted to each 
database, and the search terms were combined using ‘AND’ or 
‘OR’ operators. We inspected the references of all identified 
studies to identify additional relevant studies and to avoid 
omitting important articles.
Selection of reports and data extraction 
Firstly, the reviewer identified duplicate publications us-
ing Note Express and sorted duplicate articles into different 
classifications. An independent reviewer screened the titles 
and abstracts to determine whether articles met the inclusion 
criteria using Note Express (first scanning).
Risk-of-bias assessment
The assessment of the risk of bias in the included studies 
was based on the recommendations in the methods section 
of the Cochrane Handbook 5.1.0 [14]. The quality of each 
included study was independently assessed by XY and PD 
using the Cochrane Risk of Bias (ROB) tool. The overall risk 
level for each outcome was marked as low, high, or unclear. 
Based on these items, studies containing more than half of 
high-risk or unclear items were considered to be overall high 
risk; otherwise, they were considered low risk. Two reviewers 
discussed the results with each other to reach an agreement if 
a disagreement existed. 
Data analysis
Data was extracted from each study to perform a me-
ta-analysis using R studio software according to the data 
type. We obtained 95% confidence intervals (CIs) and mean 
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differences (MDs) to calculate the combined outcomes of 
continuous variables. The standardised mean difference (SMD) 
statistic was selected for continuous data when the outcome 
was assessed by the different scales (e.g. scores of tremor 
severity scales). Risk ratios (RRs) with 95% CIs were calcu-
lated for dichotomous data (e.g. incidence of adverse events). 
Differences were estimated to be statistically significant at 
p < 0.05. Statistical heterogeneity was calculated with Cochran’s 
Q (p < 0.1) and I2 tests (Higgins et al., 2003). If p > 0.10 and 
I2 < 50%, which indicated no homogeneity, a fixed-effects 
model was used. If p ≤ 0.10 or 50% < I2 < 75%, which indicated 
significant heterogeneity, a random-effects model was used. If 
I2 > 75%, we either conducted an exclusive sensitivity analysis 
or abandoned the meta-analysis. For the primary outcome 
of severity of tremor, we performed the following subgroup 




Using the search strategy (Tab. S1), we obtained 
1,489 potential studies (MEDLINE database (n = 187), EMBASE 
(n = 1,228), Cochrane Library (n = 49), and PsycINFO 
(n = 12). The search initially identified 1,427 potentially rele-
vant studies. After screening the literature, six RCTs [15–20] 
were ultimately included (supplementary Figure S1). 
We identified six publications reporting on 125 patients, 
with 98 subjects with tremor receiving BoNT-A injections and 
120 subjects receiving a placebo. The tremors were located in 
the hands of these patients. The intervention duration ranged 
from 4 weeks to 16 weeks. The toxin was distributed across 
7–14 injection sites with an average of nine sites per patient. 
The total dose of BoNT-A ranged from 50 to 150 international 
units (IU) per patient. The study characteristics and the con-
sistency evaluation of the extracted data are summarised in 
supplementary Table S1.
Quality assessment
Of the six included studies, three [17, 19, 20] were con-
sidered as having a low risk of bias in the domains of random 
sequence generation, selective reporting, incomplete outcome 
data and other biases. Only one study [18] was assessed as 
having a low risk of bias in the domains of blinding of outcome 
assessment and incomplete outcome data. Two trials were 
assessed as having an overall low risk of bias. Two reviewers 
discussed any discrepancies to reach an agreement. The risk 
of bias summary is presented in Figure 1. A consistency 





As shown in Figure 2A, six RCTs reported tremor severity 
in 125 participants injected with BoNT-A and 120 participants 
injected with a placebo. The overall pooled results showed 
a statistically significant reduction in tremor (SMD: -0.42, 
95% CI: -1.94 to 1.10; I2 = 96%, Fig. 2A).
Subgroup analysis
Because the pooled results of evaluating tremor severity 
exhibited high heterogeneity (p < 0.01; I2 = 96%), a subgroup 
analysis according to types of tremor  was conducted to 
investigate the sources of heterogeneity. Based on different 
types of tremor, a subgroup analysis was conducted. This 
revealed a statistically significant reduction in essential 
hand tremor (SMD: -1.31, 95% CI: -3.93 to 1.31, I2 = 97%, 
Figure 2B). The subgroup analyses showed that the BoNT-A 
group differed in terms of MS-related tremor (SMD: -1.10; 
95% CI: -2.17 to -0.04; I2 = 79%, Figure 2B) compared to 
the placebo. However, no difference existed in the outcome 
of ET hand tremor.
Figure 1. Risk of bias graph
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Figure 2B. Subgroup analyses of BoNT-A on tremor severity in meta-analysis. CI — confidence interval, IV — inverse variance, SD — standard deviation
Figure 2A. Forest plot of BoNT-A on tremor severity in meta-analysis. CI — confidence interval, SD — standard deviation
Figure 3. Forest plot of BoNT-A on grip strength in meta-analysis. CI — confidence interval, SD — standard deviation
                            Botulinum toxin type A                 Placebo  Standardised Mean   Weight Weight
 Study Total Mean SD Total  Mean SD Difference SMD    95%-CI (fixed) (random)
 Brin, M F 2001 43 1.20 1.5000 40 0.10 0.3000  0.99 [0.53; 1.45] 41.2% 17.5%
 Frederique M.C. Boonstra 2020 21 -0.79 1.1300 22 -0.06 1.3100  -0.58 [-1.20; 0.03] 23.0% 17.3%
 Jankovic J 1996 13 0.64 1.1200 12 2.33 1.0700  -1.49 [-2.40; -0.59] 10.5% 16.7%
 Mittal, S 0 2017 14 -2.00 0.2300 16 -3.00 0.2700  3.86 [ 2.59; 5.13] 5.3% 15.8%
 Mittal, Shivam Om 2018 15 -1.00 0.2800 13 0.00 0.2600 - -3.58 [-4.84; -2.33] 5.5% 15.8%
 Van Der Waft, Anneke 2012 19 -2.00 1.5300 17 0.00 0.5100  -1.68 [-2.45; -0.90] 14.4% 17.0%
 Fixed effect model 125   120    -0.12 [-0.41; 0.18]  100.0% —
 Random effects model        -0.42 [-1.94; 1.10] — 100.0%
 Heterogeneity: i2 = 96%, t2 = 3.3735, p < 0.01      –4 –2 0 2 4
                            Botulinum toxin type A                 Placebo  Standardised Mean    Weight Weight
 Study Total Mean SD Total  Mean SD Difference SMD       95%-CI  (fixed) (random)
 ET hand tremor
 Brin, M F 2001 43 1.20 1.5000 40 0.10 0.3000  0.99 [ 0.53; 1.45] 41.2% 17.5%
 Jankovic J 1996 13 0.64 1.1200 12 2.33 1.0700  -1.49 [-2.40; -0.59] 10.5% 16.7%
 Mittal, Shivam Om 2018 15 -1.00 0.2800 13 0.00 0.2600  -158 [-4.84; -233] 5.5% 15.8%
 Fixed effect model 71   65    0.10 [-0.29; 0.48] 57.2% — 
 Random effects model        -1.31 [-3.93; 1.31] — 50.0%
 Heterogeneity: i2= 97%, t2 = 5.1476, p < 0.01          
 
 MS-related tremor         
 Frederique M.G. Boonstra 2020 21 -0.79 1.1300 22 -0.06 1.3100  -0.58 [-1.20; 0.03] 23.0% 17.3%
 Van Der Watt, Anneke 2012 19 -2.00 1.5300 17 0.00 0.5100  -1.68 [-2A5; -0.90] 14.4% 17.0%
 Fixed effect model 40   39    -1.01 [-1.49; -0.53] 37.5% —
 Random effects model        -1.10 [-2.17; -0.04] — 34.2%
 Heterogeneity: i2 = 79%, t2  = 0.4689, p = 0.03         
 Parkinson’s Disease Tremor
 Mittal, S 0 2017 14 -2.00 0.2300 16 -3.00 0.2700  3.86 [ 2.59; 5.13] 5.3% 15.8%
 Fixed effect model 14   16    3.86 [ 2.59; 5.13] 5.3% —
 Random effects model        3.86 [ 2.59; 5.13] — 15.8%
 Heterogeneity not applicable         
 
 Fixed effect model 125   120    -0.12 [-0.41; 0.18] 100.0% —
 Random effects model        -0.42 [-1.94; 1.10] — 100.0%
 Heterogeneity: i2 = 96%, t2 = 3.3735, p < 0.01         
 Residual heterogeneity: i2 = 95%, p < 0.01         –4 –2 0 2 4
                                   Botulinum toxin type A                Placebo  Mean Difference          Weight        Weight
 Study Total Mean SD Total  Mean SD  MD    95%-CI         (fixed)      (random)
 Brin, M F 2001 40 -3.80 2.7200 44 1.40 3.0300  -5.20 [-6.43; -3.97] 0.5% 43.0%
 Frederique M.G. Boonstra 2020 21 -0.05 0.1200 22 -0.03 0.1600  -0.02 [-0.10; 0.06] 99.5% 44.2%
 Mittel, S 0 2017 14 6.80 17.0400 16  -1.00 13.7800  7.80 [-3.39; 18.99] 0.0% 12.8%
 Fixed effect model 75   82    0.04 [-0.13; 0.04] 100.0% —
 Random effects model        -1.25 [-5.99; 3.50] — 100.0%
 Heterogeneity: i2 = 97%, t2 = 13.2341, p < 0.01     
–15 –10–15 0 5 10 15
Grip strength
As shown in Figure 3, two RCTs reported grip strength 
in 75 participants injected with BONT-A and 82 participants 
injected with a placebo. The overall pooled results did not show 
a statistically significant improvement in grip strength (MD: 
-1.25, 95% CI: -5.99 to 3.50, I2 = 97%, Fig. 3).
Hand weakness
As shown in Figure 4, three RCTs reported an adverse 
event of hand weakness in 56 participants injected with 
BoNT-A and in 55 participants injected with a placebo. The 
overall pooled results showed a statistically significant im-
provement in hand weakness (RR: 2.96, 95% CI: 1.40 to 6.24, 
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Figure 4. Forest plot of relative risk of BoNT-A on hand weakness in meta-analysis
Figure 5. Funnel plot of publication bias of BoNT-A on tremor 
severity
I2 = 37%, Fig. 4). BoNT-A injections were effective treatments 
for patients with hand tremors, but were accompanied by 
hand weakness, particularly weakness of the finger extensors.
Kinetic tremor severity and postural tremor 
severity
Two studies reported a mean change in kinetic tremor 
severity score from baseline. The pooled results revealed that 
the BoNT-A groups performed significantly better in terms 
of kinetic tremor severity (MD: -0.69; 95% CI: -1.28 to -0.11; 
I2 = 98%, supplementary Figure S2) and postural tremor 
severity (MD: -0.79; 95% CI: -1.18 to -0.40; I2 = 95%, supple-
mentary Figure S3) than the placebo groups.
Publication bias
A funnel plot is shown in Figure 5. The number of includ-
ed studies is low, and the available tests for the assessment of 
publication bias lack statistical power. An Egger’s test accord-
ing to outcomes of tremor severity showed no publication bias 
of the included studies (Egger’s test, p = 0.71 > 0.05).
Discussion
This study included five RCTs comparing the effects of 
BoNT-A on patients with tremor and included 198 partic-
ipants. Our study found consistent evidence showing that 
injections of BoNT-A into the forearm muscles significantly 
ameliorated tremor, including the severity of upper extremity 
tremor and grip strength. 
These findings support the hypothesis that BoNT-A 
represents an alternative therapeutic option for patients with 
tremors who are unresponsive to, or intolerant of, propranolol 
or primidone. However, adverse effects of BoNT-A were ob-
served, including hand weakness and infrequently pain at the 
injection site. According to Brin et al. [15], adverse reactions 
obtained from patient responses to questionnaires throughout 
the trial showed hand weakness in 30% (13/43) of the low-
dose BoNT-A group and approximately 70% (31/45) of the 
high-dose BoNT-A group. As shown in the study by Mittal 
et al., [19] an injection of IncoA improved ET, with a low 
occurrence of significant hand weakness. Recent evidence has 
shown [13] that OnaBoNT-A injections are safe and effective 
in the treatment of hand tremor, although the authors did not 
undertake a meta-analysis. 
Between-trial heterogeneity was not observed in the me-
ta-analyses of the primary outcomes, except for the outcome of 
hand tremor in the ET subgroup. In addition, we did not ob-
serve any difference in the outcomes of grip strength in subjects 
who received the BoNT-A injection based on current evidence, 
indicating that the BoNT-A injection seems to have little impact 
on the grip strength of patients with PD, ET and MS. 
The effect of BoNT-A on muscle strength is due to a block-
ade of gamma motor efferents and muscle spindle afferents 
[21]. All included trials recruited adult patients (>18 years) 
who had received a clinical diagnosis of PD, ET, or MS with 
moderate to severe tremor that was refractory to standard 
medical treatments. The injection pattern (dose and muscle 
selection) was customised to each patient and was quantified 
based on the tremor activity on electromyography (EMG) 
and the size of the muscle. The number of injection sites in 
each patient ranged from seven to 14, with an average of nine 
sites per patient. The total dose of BoNT-A varied from 50 to 
120 units per patient (mean, 100 U per patient). In the pla-
cebo group (0.9% saline), the same techniques were utilised 
to mask the active treatment. Doses of botulinum toxin are 
usually divided into several injections, depending on the size 
of the muscle, with up to eight injection sites reported for each 
muscle [22]. This personalised muscle selection and toxin 
dose successfully ameliorated tremors [23] and reduced the 
dose-dependent adverse reactions (e.g. finger weakness and 
pain at the injection sites).
Regarding the quality of the evidence, key sources of bias ex-
ist in these studies and included the limited allocation conceal-
ment to the treatment group and the blinding of participants. 
                   Botulinum toxin type A            Placebo                            Risk Ratio         Weight         Weight
 Study Events Total Events Total     RR      95%-CI        (fixed)       (random)
 Jankovic J 1996 5 12 0 12    11.00 [0.68; 178.53] 6.6% 15.7%
 Mittal, S 0 2017 10 27 6 27    1.67 [0.71; 3.94] 79.7% 58.1%
 Van Der Walt, Anneke 2012 7 17 1 16    6.59 [0.91; 47.76] 13.7% 26.2%
 Fixed effect model  56  55    2.96 [1.40; 6.24] 100.0% —
 Random effects model        3.22 [0.94; 11.03] — 100.0%
 Heterogeneity: i2 = 37%, t = 0.4882, p = 0.20       
0.01 0.1 1 10 100
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Well-designed and implemented RCTs are the gold stand-
ard for evaluating the efficiency of interventions and providing 
outcome estimates and confidence [23, 24]. Based on our 
findings, the reporting quality of RCTs assessing the effects 
of BoNT-A on tremor is unsatisfactory. We searched the 
Clinicaltrials.gov website and identified many high-quality 
ongoing studies. We look forward to the publication of these 
high-quality studies designed to evaluate the tolerance of bot-
ulinum toxin injections as a treatment for tremor in the future.
Recommendations for practice
Regarding the clinical implications, the administration of 
BoNT-A via a fixed injection approach improves the clinical 
rating score of tremors, but a high percentage of patients 
(30–70%) develop moderate to severe hand weakness, which 
has limited its use in clinical practice. In a qualitative sum-
mary of the included evidence, the injection pattern (dose 
and muscle selection) ranged from seven to 14 sites, with an 
average of nine sites per patient, and the total dose ranged 
from 50 to 120 units per patient (mean, 100 U per patient). We 
recommend customising the injection pattern for each patient 
based on the tremor activity on electromyography (EMG) and 
the size of the muscle.
Limitations
Some limitations exist in the present study. Firstly, most of 
the included studies were pilot studies, and only five RCTs were 
included. Limited evidence of the effectiveness of BoNT-A to 
improve tremor symptoms is available, and larger randomised 
trials are required. Secondly, the number of patients included 
in the meta-analysis of the primary outcome was small, which 
may lead to false-negative results due to insufficient statistical 
power. Thirdly, heterogeneity in some domains of the risk of 
bias resulted in methodological limitations of the included 
studies. We are hopeful that more powerful evidence will be 
obtained to provide a more reliable conclusion.
We have provided a meta-analysis of all RCTs where a form 
of botulinum toxin was used to treat arm tremor. Limited 
by the small number of studies that could be included, the 
heterogeneity of tremor across the different neurological 
conditions under study would further make it difficult to make 
any disease-specific recommendation.
Conclusions
BoNT-A injections are ineffective in patients with hand 
tremors among a mixed population of patients diagnosed 
with PD, ET and MS, although subgroup analysis suggested 
that BoNT-A injections has possible benefits in MS-related 
tremor. Larger randomised trials are required to confirm the 
clinical effectiveness of BoNT-A in improving tremor. More 
research is needed to monitor the adverse events associated 
with this treatment.
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